Despite little prescriber differentiation between the JAKs, including satisfaction and manufacturer perceptions, Olumiant is projected to maintain a significant market
Fewer than half of those dealing with Parkinson’s disease in the United States are able to gain clinical control of
Prior to launch, prescribers estimate that TNF inhibitors are likely to bear the greatest brunt of increased adoption of the
PHILADELPHIA — Results of a survey conducted in the U.S. and abroad showed that most nephrologists remain wary about prescribing
Lupus patients desire more targeted information on specific treatments available, underscoring an opportunity for the pharmaceutical industry to play a
Gene therapies and LRRK2 inhibition are at the forefront of prescribers’ interest, highlighting the need for a truly disease modifying
Despite Vabysmo’s gains in 2023, Eylea HD will prove to be a formidable force in the coming year. [Exton PA,
According to Spherix Global Insights, US nephrologists have expressed a high level of enthusiasm for Novartis’ iptacopan and atrasentan, as
With competition finally hitting the US market, branded adalimumab (Humira) is finally losing market share, according to the third quarter update of
In both the U.S. and Europe, clinicians want to limit treatment with glucocorticoids — steroid hormones whose long-term use for
Oral drugs have raced to the front of the pack in the crowded migraine therapy space and appear to be
Despite overall biologic growth in both geographies, use of advanced systemic treatments in the US outpaces the EU5. EXTON, PA.,
